Nesta Snider
 |
Two other OCs--Loestrin and Mircette--contain 20 mcg Ethinyl Estradiol, but differ in their Progestin component or dose. Berlex introduces new 20 mcg birth control pill.Another low-dose oral contraceptive (OC), Levlite, has received US Food and Drug Administration approval. Apolipoprotein B increased in all contraceptives preparations. Headache, reported by 17.3% of study participants, was the most com side effect.. (1) monophasic desogestrel (150/30), (2) monophasic desogestrel (150/20, containing 20 micrograms of ethinyl estradiol instead of 30 micrograms of ethinyl estradiol, (3) biphasic desogestrel, (4) monophasic levonorgestrel (150/30), and (5) triphasic levonorgestrel. Clinical trials involving 755 US women signed that Levlite provides high contraceptive efficacy with good cycle control. Levlite, manufactured by Berlex Laboratories, contains 20 mcg Ethinyl Estradiol contraceptives and 100 mcg Levonorgestrel. The antiatherogenic indexes (ratios of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol and apolipoprotein A-I to apolipoprotein seasonale B were higher for monophasic desogestrel (150/30) and biphasic desogestrel than for comparable levonorgestrel-containing preparations. The monophasic desogestrel (150/30) and biphasic desogestrel preparations induced higher high-density lipoprotein cholesterol and apolipoprotein jolessa A-I levels than did their levonorgestrel-containing counterparts. A pill containing 20 mcg Ethinyl Estradiol provides women with 33% less Estrogen than a 30-mcg pill. Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations.The effects of three different desogestrel-containing combined oral contraceptive preparations on lipid metabolism were compared with those of two levonorgestrel preparations. The following preparations were studied. The effects of these preparations were assessed on high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A-I, apolipoprotein B, the ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol, and the ratio of apolipoprotein A-I to apolipoprotein B after 3 months of treatment, and the percentage changes with regard to pretreatment were calculated. Alesse, an OC manufactured by Wyeth-Ayerst, has the same components. Low-density lipoprotein cholesterol levels were increased in monophasic levonorgestrel and clearly decreased in the lowest ethinyl estradiol-containing monophasic desogestrel (150/20) and biphasic desogestrel preparations. The differences seen between the desogestrel and levonorgestrel preparations can best be explained by the lower intrinsic androgenicity of 3-keto-desogestrel (active metabolite of desogestrel) than that of levonorgestrel.
|